Bayer Proposes $7.25 Billion Glyphosate Settlement as Stock Slumps 8%

Glyphosate has once again become a central issue for Bayer, the German pharmaceutical and crop-science giant, as it proposed a $7.25 billion settlement to resolve tens of thousands of U.S. lawsuits tied to claims that Roundup weedkiller caused cancer. This massive legal move sent Bayer’s stock sharply lower, causing concern among investors and shaking the broader stock market sentiment. The company faces years of litigation costs and ongoing uncertainty about the future of its glyphosate-based products.